Corrigendum to “Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer” [Crit. Rev. Oncol. Hematol. 137, May (2019) 57–83]

González-Ávila, Georgina; Sommer, Bettina; Mendoza-Posada, Daniel; Ramos, Carlos; García-Hernández, Alejandra; Falfán-Valencia, Ramcés

doi:10.1016/j.critrevonc.2019.04.017

Cited by 12 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the cell, the upregulation of proteolytic enzymes degrading the gelatin chains, such as the MMP-2, can trigger the release of LY from the nanosystem, making the DNP-AuNPs-LY@Gel a stimuliresponsive drug delivery system. [30]…”

Section: (4 Of 14)mentioning

confidence: 99%

SERS Quantification of Galunisertib Delivery in Colorectal Cancer Cells by Plasmonic‐Assisted Diatomite Nanoparticles

Managò

Tramontano

Cave

et al. 2021

Small

View full text Add to dashboard Cite

therapies for CRC treatment, like systemic chemotherapy and immunotherapy, are expensive and invasive since they fail to target cancer cells selectively, causing severe toxicity on normal tissues besides side effects. [2][3][4][5] The epithelial-to-mesenchymal transition (EMT) is a dynamic multistep process involved in several physiological and pathological conditions, including cancer. [6] Notably, EMT in CRC is associated with an invasive, metastatic, and chemoresistant phenotype. [7] In contrast, the mesenchymal-to-epithelial transition (MET), is the reverse program of EMT in metastases and is characterized by the upregulation of epithelial adhesive proteins such as E-CADHERIN, and downregulation of mesenchymal proteins, such as SNAIL-1 and TWIST-1. Slowing EMT or even reversing the process in metastases inducing a MET program not only is a powerful therapeutic approach alone, but can also assist in increasing the efficacy of other anticancer treatments. Among the molecular pathways promoting tumorigenesis in CRC, the transforming growth factor-β (TGF-β) is described as a crucial factor in EMT induction. [8] Fighting the CRC with the TGF-β receptor I-specific inhibitor Galunisertib (LY2157299, LY) has been proposed as a powerful strategy to reduce tumor growth and the risk of relapse. [8] However, LY is cleared predominantly by cytochrome P450 3A4 (CYP3A4) oxidative metabolism in the The small molecule Galunisertib (LY2157299, LY) shows multiple anticancer activities blocking the transforming growth factor-β1 receptor, responsible for the epithelial-to-mesenchymal transition (EMT) by which colorectal cancer (CRC) cells acquire migratory and metastatic capacities. However, frequent dosing of LY can produce highly toxic metabolites. Alternative strategies to reduce drug side effects can rely on nanoscale drug delivery systems that have led to a medical revolution in the treatment of cancer, improving drug efficacy and lowering drug toxicity. Here, a hybrid nanosystem (DNP-AuNPs-LY@Gel) made of a porous diatomite nanoparticle decorated with plasmonic gold nanoparticles, in which LY is retained by a gelatin shell, is proposed. The multifunctional capability of the nanosystem is demonstrated by investigating the efficient LY delivery, the enhanced EMT reversion in CRCs and the intracellular quantification of drug release with a sub-femtogram resolution by surface-enhanced Raman spectroscopy (SERS). The LY release trigger is the pH sensitivity of the gelatin shell to the CRC acidic microenvironment. The drug release is real-time monitored at single-cell level by analyzing the SERS signals of LY in CRC cells. The higher efficiency of LY delivered by the DNP-AuNPs-LY@Gel complex paves the way to an alternative strategy for lowering drug dosing and consequent side effects.

show abstract

Section: (4 Of 14)mentioning

confidence: 99%

SERS Quantification of Galunisertib Delivery in Colorectal Cancer Cells by Plasmonic‐Assisted Diatomite Nanoparticles

Managò

Tramontano

Cave

et al. 2021

Small

View full text Add to dashboard Cite

show abstract

“…There is growing evidence showing that tumour metastasis is a series of sequential and complex processes. 61 Firstly, epithelialmesenchymal transition (EMT) empowers tumour cells to break through the extracellular matrix, and then metastatic cells endocytose out of the vascular wall and migrate to a new metastatic site. Current studies on tumour bacteria have shown that low biomass intra-tumoral bacteria can act on the above metastatic processes.…”

Section: Bacteria and Tumour Metastasismentioning

confidence: 99%

Drug delivery systems for enhanced tumour treatment by eliminating intra-tumoral bacteria

Liu,

Ma,

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…EVs are highly heterogeneous and differ in terms of their biogenesis, size (~30-1000 nm) and molecular compositions (lipid bilayers, ncRNAs, proteins and small molecules) [87]. EVs, including exosomes are readily accessible from patient liquid biopsies and recent studies indicate that EV-associated metalloproteinases have complex roles in cancer metastasis [87][88][89]. Lung cancer is a leading cause of cancer-related deaths and early detection could positively impact patient outcomes [90].…”

Section: Metalloproteinase Detectionmentioning

confidence: 99%

AL-PHA beads: bioplastic-based protease biosensors for global health applications

Kelwick

Webb

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Proteases are multi-functional proteolytic enzymes that have complex roles in human health and disease. Therefore, the development of protease biosensors can be beneficial to global health applications. To this end, we developed Advanced proteoLytic detector PolyHydroxyAlkanoates (AL-PHA) beads, a library of over 20 low-cost, biodegradable, bioplastic-based protease biosensors. Broadly, these biosensors utilise PhaC-reporter fusion proteins that are bound to microbially manufactured polyhydroxyalkanoate beads. In the presence of a specific protease, superfolder green fluorescent reporter proteins are cleaved from the AL-PHA beads - resulting in a loss of bead fluorescence. The Tobacco Etch Virus (TEV) AL-PHA biosensor detected the proteolytic activity of at least 1.85 pM of AcTEV. AL-PHA beads were also engineered to detect cercarial elastase from Schistosoma mansoni-derived cercarial transformation fluid (SmCTF) samples, as well as cancer-associated metalloproteinases in extracellular vesicle and cell-conditioned media samples. We envision that AL-PHA beads could be further developed for use in resource-limited settings.

show abstract

Corrigendum to “Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer” [Crit. Rev. Oncol. Hematol. 137, May (2019) 57–83]

Cited by 12 publications

References 0 publications

SERS Quantification of Galunisertib Delivery in Colorectal Cancer Cells by Plasmonic‐Assisted Diatomite Nanoparticles

SERS Quantification of Galunisertib Delivery in Colorectal Cancer Cells by Plasmonic‐Assisted Diatomite Nanoparticles

Drug delivery systems for enhanced tumour treatment by eliminating intra-tumoral bacteria

AL-PHA beads: bioplastic-based protease biosensors for global health applications

Contact Info

Product

Resources

About